TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval

Core Insights - TG Therapeutics (NASDAQ: TGTX) shares reached new 52-week highs, driven by additional data on Briumvi, enhancing the company's market position [2]. Company Overview - TG Therapeutics is focusing on capturing market share with its product Briumvi, which has shown promising data [2]. Investment Strategy - The Growth Stock Forum provides a model portfolio of 15-20 stocks, a top picks list of up to 10 stocks expected to perform well, and trading ideas targeting short-term and medium-term moves [2].